COSTA MESA, Calif.--(BUSINESS WIRE)--Oxygen Biotherapeutics, Inc. (OTCBB:OXBO) today announced that the company has filed a response to the FDA’s request for information and that the filing also includes a synopsis of the company’s revised protocol for a Phase II dose escalation clinical trial of Oxycyte® in Traumatic Brain Injury (TBI). Oxycyte is the Company’s perfluorocarbon (PFC) therapeutic oxygen carrier.
